The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., & Pollak, M. (1998) · Science · doi:10.1126/science.279.5350.563 · Cited by 1,996
Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
Bunone, G., Briand, P. A., Miksicek, R. J., & Picard, D. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00571.x · Cited by 986
Čulig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G., & Klocker, H. (1994) · PubMed · Cited by 938
Glass, C. K., Rose, D. W., & Rosenfeld, M. G. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80066-x · Cited by 698
Pietras, R. J., Arboleda, J., Dm, R., Wongvipat, N., Pegram, M. D., Ramos, L., Cm, G., Mg, P., Sliwkowski, M. X., & Dj, S. (1995) · PubMed · Cited by 603
Dopaminergic and Ligand-Independent Activation of Steroid Hormone Receptors
Power, R. F., Mani, S. K., Codina, J., Conneely, O. M., & O'Malley, B. W. (1991) · Science · doi:10.1126/science.1749936 · Cited by 567
Research works printed but not linked: 7
- Leitzel, K. et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J. Clin. Oncol. 13, 1129–1135 (1995). · DOI
- Ware, J.L., Maygarden, S.J., Koontz, W.W. Jr. & Strom, S.C. Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate. Hum. Pathol. 22, 254–258 (1991). · doi:10.1016/0046-8177(91)90159-m
- Lyne, J.C. et al. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biological effects on prostate cancer cells in vitro. Cancer J. Sci. Am. 3, 21–30 (1997).
- Ross, J.S. et al. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 79, 2162–2170 ( 1997). · doi:10.1002/(sici)1097-0142(19970601)79:11<2162::aid-cncr14>3.0.co;2-u
- Arai, Y., Tatsuhiro, T. & Yoshida, O. c-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer. Prostate 30, 195– 201 (1997). · doi:10.1002/(sici)1097-0045(19970215)30:3<195::aid-pros8>3.0.co;2-l
- Romijn, J.C., Verkoelen, C.F. & Schroeder, F.H. Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects. Prostate 12, 99–110 (1988). · doi:10.1002/pros.2990120112
- Cobleigh, M.A. et al. Efficacy and safety of HerceptinTM (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Progr/Proc. Am. Soc. Clin. Oncol. 17, 97a (1998).
Cited by
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Self-citationAndrogen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Self-citationMolecular genetics of prostate cancer: new prospects for old challenges
Shen, M. M., & Abate-Shen, C. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 946
Nelson, W. G., De Marzo, A. M., & Isaacs, W. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021562 · Cited by 918
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873
Locke, J. A., Guns, E. S., Lubik, A. A., Adomat, H. H., Hendy, S. C., Wood, C. A., Ettinger, S. L., Gleave, M. E., & Nelson, C. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5997 · Cited by 747
The Androgen Axis in Recurrent Prostate Cancer
Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1146-03 · Cited by 675
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis
Massie, C. E., Lynch, A., Ramos‐Montoya, A., Boren, J., Stark, R., Fazli, L., Warren, A., Scott, H., Madhu, B., Sharma, N., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.158 · Cited by 624
The role of HER2 in cancer therapy and targeted drug delivery
Tai, W., Mahato, R., & Cheng, K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.009 · Cited by 555
Androgen Receptor Signaling in Androgen-Refractory Prostate Cancer
Grossmann, M. E., Huang, H., & Tindall, D. J. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.22.1687 · Cited by 548
Mostaghel, E. A., Page, S. T., Lin, D. W., Fazli, L., Coleman, I. M., True, L. D., Knudsen, B., Hess, D. L., Nelson, C. C., Matsumoto, A. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3332 · Cited by 529
(2001) · PubMed · Cited by 500
Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines
Mukhopadhyay, A., Bueso-Ramos, C., Chatterjee, D., Pantazis, P., & Aggarwal, B. B. (2001) · Oncogene · doi:10.1038/sj.onc.1204997 · Cited by 441
Overexpression of ErbB2 in cancer and ErbB2-targeting strategies
Yu, D., & Hung, M.-C. (2000) · Oncogene · doi:10.1038/sj.onc.1203972 · Cited by 430
Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer
Pienta, K. J., & Bradley, D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0067 · Cited by 430
Lu, N. Z., Wardell, S. E., Burnstein, K. L., Defranco, D., Fuller, P. J., Giguere, V., Hochberg, R. B., McKay, L., Renoir, J.-M., Weigel, N. L., et al. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.9 · Cited by 426
Androgen receptors in hormone-dependent and castration-resistant prostate cancer
Shafi, A. A., Yen, A. E., & Weigel, N. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.003 · Cited by 420
Her-2-neu Expression and Progression Toward Androgen Independence in Human Prostate Cancer
Signoretti, S. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.23.1918 · Cited by 397
Targeting the androgen receptor pathway in prostate cancer
Chen, Y., Sawyers, C. L., & Scher, H. I. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.07.005 · Cited by 389
Self-citationUeda, T., Bruchovsky, N., & Sadar, M. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108255200 · Cited by 381
Shi, X.-B., Xue, L., Yang, J., Ma, A.-H., Zhao, J., Xu, M., Tepper, C. G., Evans, C. P., Kung, H.-J., & deVere White, R. W. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706641104 · Cited by 378
Graff, J. R., Konicek, B. W., McNulty, A. M., Wang, Z., Houck, K., Allen, S., Paul, J. D., Hbaiu, A., Goode, R. G., Sandusky, G. E., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003145200 · Cited by 378
Regulation of androgen receptor activity by tyrosine phosphorylation.
Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., Nesheiwat, I., Kong, X., Melamed, J., Handratta, V. D., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.021 · Cited by 364
Mellinghoff, I. K., Vivanco, I., Kwon, A., Tran, C., Wongvipat, J., & Sawyers, C. L. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.031 · Cited by 344
Drug resistance in metastatic castration-resistant prostate cancer
Seruga, B., Ocana, A., & Tannock, I. F. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.136 · Cited by 336
Liu, B., Lee, H.-Y., Weinzimer, S. A., Powell, D. R., Clifford, J. L., Kurie, J. M., & Cohen, P. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002547200 · Cited by 326
Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein
Li, Y., Upadhyay, S., Bhuiyan, M., & Sarkar, F. H. (1999) · Oncogene · doi:10.1038/sj.onc.1202650 · Cited by 319
Rocchi, P., So, A., Kojima, S., Signaevsky, M., Beraldi, E., Fazli, L., Hurtado-coll, A., Yamanaka, K., & Gleave, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3998 · Cited by 316
Fatty acid synthase: A metabolic oncogene in prostate cancer?
Baron, A., Migita, T., Tang, D., & Loda, M. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10708 · Cited by 292
Molecular cell biology of androgen receptor signalling
Bennett, N. C., Gardiner, R. A., Hooper, J. D., Johnson, D. W., & Gobe, G. C. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.11.013 · Cited by 292
Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.
Zhu, M.-L., & Kyprianou, N. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0084 · Cited by 286
Androgen receptor signaling in prostate cancer
Culig, Z., & Santer, F. R. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9474-0 · Cited by 283
Soy isoflavones and prostate cancer: A review of molecular mechanisms
Mahmoud, A. M., Yang, W., & Bosland, M. C. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.12.010 · Cited by 281
Glucocorticoid Receptor Phosphorylation Differentially Affects Target Gene Expression
Chen, W., Dang, T., Blind, R. D., Wang, Z., Cavasotto, C. N., Hittelman, A. B., Rogatsky, I., Logan, S. K., & Garabedian, M. J. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0219 · Cited by 280
Mahajan, N. P., Liu, Y., Majumder, S., Warren, M. R., Parker, C. E., Mohler, J. L., Earp, H. S., & Whang, Y. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700420104 · Cited by 274
Interleukin-6 regulation of prostate cancer cell growth.
Culig, Z., Steiner, H., Bartsch, G., & Hobisch, A. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20477 · Cited by 269
Androgen receptor as a target in androgen-independent prostate cancer
Balk, S. P. (2002) · Urology · doi:10.1016/s0090-4295(02)01593-5 · Cited by 264
Interleukin-6 and prostate cancer progression
SMITH, P., HOBISCH, A., LIN, D., CULIG, Z., & KELLER, E. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(00)00021-6 · Cited by 264
Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression
Jin, X., Ding, D., Yan, Y., Li, H., Wang, B., Ma, L., Ye, Z., Ma, T., Wu, Q., Rodrigues, D. N., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.10.034 · Cited by 257
Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
Attard, G., Cooper, C. S., & de Bono, J. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.11.006 · Cited by 242
Dango, S., Mosammaparast, N., Sowa, M. E., Xiong, L.-J., Wu, F., Park, K., Rubin, M., Gygi, S., Harper, J. W., & Shi, Y. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.039 · Cited by 216
Influence of Sex Hormones on Cancer Progression
Folkerd, E. J., & Dowsett, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4290 · Cited by 229
Malinowska, K., Neuwirt, H., Cavarretta, I. T., Bektic, J., Steiner, H., Dietrich, H., Moser, P. L., Fuchs, D., Hobisch, A., & Culig, Z. (2009) · Endocrine Related Cancer · doi:10.1677/erc-08-0174 · Cited by 157
Miyake, H., Nelson, C., Rennie, P. S., & Gleave, M. E. (2000) · Endocrinology · doi:10.1210/endo.141.6.7520 · Cited by 146
Androgen axis in prostate cancer.
Culig, Z., & Bartsch, G. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20898 · Cited by 102
Asim, M., Siddiqui, I. A., Hafeez, B. B., Baniahmad, A., & Mukhtar, H. (2008) · Oncogene · doi:10.1038/sj.onc.1211016 · Cited by 101
Shepherding AKT and androgen receptor by Ack1 tyrosine kinase.
Mahajan, K., & Mahajan, N. P. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22162 · Cited by 92
Androgen receptor decoy molecules block the growth of prostate cancer.
Quayle, S. N., Mawji, N. R., Wang, J., & Sadar, M. D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606718104 · Cited by 84
Hypoxia Increases Androgen Receptor Activity in Prostate Cancer Cells
Park, S.-Y., Kim, Y.-J., Gao, A. C., Mohler, J. L., Onate, S. A., Hidalgo, A. A., Ip, C., Park, E.-M., Yoon, S. Y., & Park, Y.-M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1341 · Cited by 81
Kinases and protein phosphorylation as regulators of steroid hormone action
Weigel, N. L., & Moore, N. L. (2007) · Nuclear Receptor Signaling · doi:10.1621/nrs.05005 · Cited by 72
HER3 Is an Actionable Target in Advanced Prostate Cancer
Gil, V., Miranda, S., Riisnaes, R., Gurel, B., D’Ambrosio, M., Vasciaveo, A., Crespo, M., Ferreira, A., Brina, D., Troiani, M., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-3360 · Cited by 68
Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer.
Lyons, L. S., Rao, S., Balkan, W., Faysal, J., Maiorino, C. A., & Burnstein, K. L. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0158 · Cited by 67
Androgen Receptor Mutations in Carcinoma of the Prostate: Significance for Endocrine Therapy
Culig, Z., Klocker, H., Bartsch, G., & Hobisch, A. (2001) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200101040-00001 · Cited by 50
The Drug-Induced Degradation of Oncoproteins: An Unexpected Achilles' Heel of Cancer Cells?
Ablain, J., Nasr, R., Bazarbachi, A., & de Thé, H. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0087 · Cited by 44
Interplay between steroid signalling and microRNAs: implications for hormone-dependent cancers
Fletcher, C. E., Dart, D. A., & Bevan, C. L. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0208 · Cited by 37
Agoulnik, I. U., Bingman, W. E., Nakka, M., Li, W., Wang, Q., Liu, X. S., Brown, M., & Nancy L., N. L. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0481 · Cited by 36
Metadata
- Authors
- Craft, N., Shostak, Y., Carey, M., & Sawyers, C. L.
- Venue
- Nature Medicine
- Published
- 1999-03
- Volume
- 5
- Issue
- 3
- Pages
- 280-285
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- DOI
- 10.1038/6495
- OpenAlex
- W1580523172
- Cited by
- 980
- References
- 38
- FWCI
- 56.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.